- Home
- PWP vs MNKD Comparison
PWP vs MNKD Comparison
Compare PWP & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PWP
- MNKD
- Stock Information
- Founded
- PWP 2006
- MNKD 1991
- Country
- PWP United States
- MNKD United States
- Employees
- PWP N/A
- MNKD N/A
- Industry
- PWP Finance: Consumer Services
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- PWP Finance
- MNKD Health Care
- Exchange
- PWP Nasdaq
- MNKD Nasdaq
- Market Cap
- PWP 1.3B
- MNKD 1.2B
- IPO Year
- PWP N/A
- MNKD 2004
- Fundamental
- Price
- PWP $22.35
- MNKD $3.69
- Analyst Decision
- PWP Hold
- MNKD Buy
- Analyst Count
- PWP 3
- MNKD 6
- Target Price
- PWP $23.67
- MNKD $9.17
- AVG Volume (30 Days)
- PWP 1.3M
- MNKD 3.1M
- Earning Date
- PWP 08-01-2025
- MNKD 08-06-2025
- Dividend Yield
- PWP 1.23%
- MNKD N/A
- EPS Growth
- PWP N/A
- MNKD 149.32
- EPS
- PWP 0.90
- MNKD 0.11
- Revenue
- PWP $871,012,000.00
- MNKD $301,736,000.00
- Revenue This Year
- PWP $3.95
- MNKD $13.62
- Revenue Next Year
- PWP $20.19
- MNKD $15.18
- P/E Ratio
- PWP $25.36
- MNKD $34.29
- Revenue Growth
- PWP 20.01
- MNKD 21.48
- 52 Week Low
- PWP $14.12
- MNKD $3.38
- 52 Week High
- PWP $27.03
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- PWP 62.03
- MNKD 45.90
- Support Level
- PWP $21.20
- MNKD $3.38
- Resistance Level
- PWP $22.95
- MNKD $3.81
- Average True Range (ATR)
- PWP 0.96
- MNKD 0.18
- MACD
- PWP 0.08
- MNKD -0.01
- Stochastic Oscillator
- PWP 86.01
- MNKD 35.14
About PWP Perella Weinberg Partners
Perella Weinberg Partners is an independent advisory firm that provides strategic and financial advice to a wide range of clients. The Company's activities as an investment banking advisory firm constitute a single business segment that provides a range of advisory services, including advice related to strategic and financial decisions, mergers and acquisitions execution, shareholder and defense advisory, financing and capital solutions advice with resources focused on restructuring and liability management, capital markets advisory, private capital placement, as well as specialized underwriting and research services for the energy and related industries.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.